Hypertriglyceridemia clinical trials

Explore recruiting hypertriglyceridemia clinical trials.

Recruiting hypertriglyceridemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypertriglyceridemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ISIS 678354-CS9: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia

Denmark, Spain, France, Poland, Bulgaria, Netherlands +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (SHTG)

Bulgaria, Hungary, Poland, France, Spain, Czechia +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia (SHTG)

Spain, Poland, Hungary, Latvia, Austria, Bulgaria +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PHASE 3 OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PLOZASIRAN IN ADULTS WITH HYPERTRIGLYCERIDEMIA (SHASTA-10 STUDY)

Lithuania, Poland, Latvia, Slovakia, Bulgaria, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-3 Study)

Poland, Belgium, Czechia, Spain, Slovakia, Croatia +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study)

Slovakia, France, Czechia, Spain, Germany, Bulgaria +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hypertriglyceridemia trials by city

Hypertriglyceridemia in Toronto Hypertriglyceridemia in Vancouver Hypertriglyceridemia in Montreal Hypertriglyceridemia in Calgary Hypertriglyceridemia in Edmonton Hypertriglyceridemia in Ottawa Hypertriglyceridemia in Winnipeg Hypertriglyceridemia in Quebec City Hypertriglyceridemia in Hamilton Hypertriglyceridemia in Kitchener Hypertriglyceridemia in London Hypertriglyceridemia in Halifax Hypertriglyceridemia in New York Hypertriglyceridemia in Los Angeles Hypertriglyceridemia in Chicago Hypertriglyceridemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease